Redeye thinks FlexQube’s Q4 report was better than expected due to the high gross margin and the cos...
STENOCARE published on February 22nd its year-end report for 2023.
NOSIUM har publicerat bolagets delårsrapport för det fjärde kvartalet 2023.
Redeye comments on last night’s news about a 92.3% secured rights issue of SEK19.
Redeye gives a short comment on the exciting news that the FDA and IRLAB have an aligned view on a f...
Sales exceeded expectations at SEK40.4m, compared to our estimate of SEK35m.
Eevia Health Plc (publ) (”Eevia Health”, “Eevia” or “the Company”) concludes a transformative 2023, ...
Nettoomsättningen för det fjärde kvartalet uppgick till 9,7 MEURO (8,1), vilket motsvarade en ökning...
Högre motiverat värde Vi höjer vårt motiverade värde till 49-59 kr (43-53) per aktie på grund av ett...
Idag publicerade Fable Media (tidigare Future Gaming) sin delårsrapport för kv4 2023.
Redeye updates its view of Nanexa following the Q4 report and recent events in the company.
Redeye states the report aligned with our sales estimate, but periodization effects and organization...
Sales SEK 553m -8% vs. ABGSCe 599m Adj. EBIT ~SEK -5m vs.
Redeye provides its initial take on ADDvise’s Q4 2023 report, which came in moderately below our est...
Cereno Scientific is a clinical-stage biotech, developing treatments for cardiovascular diseases (CV...
SSH Communications Security Q4 report came in weaker than expected.
Redeye provides its initial comments on the Q4 2023 report from Fragbite.
Apart from the new label, Tarpeyo is supported by a higher price and 50-51% growth in prescribers an...
Artscape and Borosan temporary margin dampeners We forecast 10% EBITA growth in '24e Accumulated FCF...
Redeye comments on Thunderful Group’s Q4'23 report, which came in line with preliminary figures.
